{"id":359480,"date":"2025-11-06T09:30:14","date_gmt":"2025-11-06T09:30:14","guid":{"rendered":"https:\/\/www.europesays.com\/us\/359480\/"},"modified":"2025-11-06T09:30:14","modified_gmt":"2025-11-06T09:30:14","slug":"how-can-you-call-everyone-else-dhoka-delhi-high-court-questions-patanjalis-new-chyawanprash-ad","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/359480\/","title":{"rendered":"How can you call everyone else &#8220;dhoka&#8221;? Delhi High Court questions Patanjali&#8217;s new chyawanprash ad"},"content":{"rendered":"<p>Dabur India has sued Patanjali, accusing them of defamation, disparagement and unfair competition over a recent television commercial for Patanjali Special Chyawanprash.<\/p>\n<p>According to the plaint, the ad features Baba Ramdev warning consumers that \u201cmost people are being duped in the name of Chyawanprash,\u201d calling other brands \u201cDhoka\u201d (fraud or deception). The ad promotes Patanjali\u2019s product as the only \u201coriginal\u201d Chyawanprash offering the \u201ctrue power of Ayurveda.\u201d<\/p>\n<p>Dabur has alleged that the commercial deliberately maligns its own flagship product, Dabur Chyawanprash, which has dominated the market since 1949 with over 61% market share, and misleads consumers into distrusting all other Chyawanprash makers.<\/p>\n<p>The plaint states that such messaging constitutes \u201cgeneric disparagement\u201d of the entire Chyawanprash category, eroding consumer faith in Ayurveda-based health supplements.<\/p>\n<p>The company further accuses Patanjali of making false claims that its Chyawanprash contains \u201c51 Ayurvedic herbs and saffron,\u201d despite a 2014 government advisory deeming the same claim misleading.<\/p>\n<p>Further, it contends that the use of \u201cSpecial\u201d as a prefix to a classical Ayurvedic medicine violates Rule 157(1-B) of the Drugs Rules, which prohibits deceptive labelling of Ayurvedic formulations.<\/p>\n","protected":false},"excerpt":{"rendered":"Dabur India has sued Patanjali, accusing them of defamation, disparagement and unfair competition over a recent television commercial&hellip;\n","protected":false},"author":3,"featured_media":359481,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[28609,28612,210,1060,28611,67,132,68],"class_list":{"0":"post-359480","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-dabur","9":"tag-delhi-high-court","10":"tag-health","11":"tag-medication","12":"tag-patanjali","13":"tag-united-states","14":"tag-unitedstates","15":"tag-us"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/359480","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=359480"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/359480\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/359481"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=359480"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=359480"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=359480"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}